Engineered immune cells take on Hard-to-Treat kidney cancer

NCT ID NCT07551349

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This study tests a new treatment for adults with advanced or metastatic clear cell kidney cancer that has not responded to standard therapies. The treatment uses specially engineered natural killer (NK) cells from a donor that are designed to target two proteins (CD70 and CAIX) on cancer cells. The goal is to see if this approach is safe and can shrink tumors or slow the disease. About 36 participants will receive the cells after a short chemotherapy course to prepare their immune system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA